The authors reply

New England Journal of Medicine

Volumn 372, Issue 19, 2015, Pages 1868-

  Schlumberger, Martin ^a   Tahara, Makoto ^b   Wirth, Lori J ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENVATINIB; PLACEBO; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

CONTROLLED CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENERAL CONDITION DETERIORATION; HUMAN; LETTER; PRIORITY JOURNAL; SUDDEN DEATH; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; THYROID NEOPLASMS;

FEMALE; HUMANS; MALE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; THYROID NEOPLASMS;

EID: 84928953700     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1503150     Document Type: Letter

References (5)

1. M Schlumberger M Tahara LJ Wirth Lenvatinib versus placebo in radioiodine-refractory thyroid cancer N Engl J Med 372 2015 621 630
2. A Ravaud M Schmidinger Clinical biomarkers of response in advanced renal cell carcinoma Ann Oncol 24 2013 2935 2942
3. R Dienstmann I Brana J Rodon J Tabernero Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs Oncologist 16 2011 1729 1740
4. L Horsley K Marti GC Jayson Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy Expert Opin Drug Metab Toxicol 8 2012 283 293
5. N Koyama K Saito Y Nishioka Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib BMC Cancer 14 2014 530 530